Lupus Erythematosus, Systemic
Conditions
Brief summary
The purpose of this study is to determine how B cell subsets and autoantibodies are related to disease remission after rituximab treatment in subjects with Systemic Lupus Erythematosus (SLE).
Detailed description
Immune cells are an important part of the abnormal autoimmune response in SLE. The B cell is a significant part of this autimmune response because it produces the antibodies which can react with normal tissue of the body. B cells have the ability to accumulate and promote the development of SLE. The purpose of this study is to determine how B cell subsets and autoantibodies are related to disease remission after rituximab treatment in subjects with SLE. This study will last approximately two years and consist of 15 study visits. These visits will occur at screening, baseline, Days 0 and 14, and Months 1, 2, 3, 4, 6, 9, 12, 15, 18, 21, and 24. Participants will receive a single rituximab injection on Days 0 and 14. Medication history and blood tests will occur at every study visit. A physical exam, medical history, and urine tests will occur at most visits. For females, a pregnancy test will occur at selected visits.
Interventions
DRUGRituximab
1000 mg administered intravenously
Sponsors
National Institute of Allergy and Infectious Diseases (NIAID)
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
19 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
* Diagnosis of SLE * Positive ANA with a titer of at least 1:160 * Active disease (one or more modified BILAG A or B) or inability to lower steroids to leass than 20 mg/day. More information about this criterion can be found in the protocol. * For females, must agree to use effective birth control methods for the duration of the study
Exclusion criteria
* Severe thrombocytopenia * Active, moderate, or severe proliferative glomerulonephritis * Active CNS manifestations due to lupus other than migraines, mild cognitive dysfunction, or mood disorders. More information about this criterion can be found in the protocol. * Poorly controlled anti-phospholipid syndrom * Significant organ dysfunction * Conditions, other than SLE, that are likely to require prolonged systemic steroids * Chronic infections. More information about this criterion can be found in the protocol. * Hepatitis B infection * Hepatitis C infection * Deep space infection within two years of study entry * Severe bacterial infection within three months of study entry * More than one severe bacterial infection within two years of study entry * Positive purified protein derivative tuberculin skin test * History of cancer, not including basal cell carcinomas and carcinoma in situ of the cervix with documentation of successful treatment * Alcohol or drug abuse * Surgery within three months of study entry * Immunization with a live vaccine within two months of study entry * Any immunization within one month of study entry * Received cyclophosphamide or calcineurin inhibitors within six months of study entry * Received anti-TNF alpha antibody within 3 months of study entry * Received etanercept within one month of study entry * Received anti-CD20 antibodies or other lymphocyte depleting antibodies * Received Immunoglobin G infusion protein or monoclonal antibody * Treatment with FDA non-approved agents within six months of study entry * Transaminases greater than two times the upper limit of normal * Pregnant or breastfeeding
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Ratio of B and T cell subsets among those with and without a long-term response and those with and without baseline anti-RBP antibody | Day 0 through month 24 |
Secondary
| Measure | Time frame |
|---|---|
| Impact of prolonged B cell absence on the composition and activation status of helper T cell subsets and regulatory T cells | Day 0 through month 24 |
| Effect of B cell depletion on interferon-alpha activity | Day 0 through month 24 |
Countries
United States
Outcome results
None listed